In vitro and so-called in vivo crosslinking are two sample states for the same chemical idea, not two reliability ranks. In vitro treats a protein or a lysate that is already open. In-cell work, which this field often labels in vivo, treats intact cells with a membrane-permeable reagent and opens them after the quench. Neither state simulates a physiological environment by adjusting temperature, pH, or salt. Neither state captures dynamic interactions without perturbing the cell.

A bifunctional reagent still writes covalent bonds between nearby, accessible groups. Mass spectrometry can name linked peptides. It does not confirm crosslinking distances. For the shared wet order that both states join after the pulse, What Is the Protocol for Crosslinking-Based Protein Interaction Analysis? provides a complementary protocol page.

Researchers who already know which compartment will be pulsed and need a residue-pair table can also review the MtoZ Biolabs Crosslinking Mass Spectrometry Protein Interaction Analysis Service for project-specific feasibility and analysis planning.

In Vitro: The Sample Is Already Open

The original test-tube description remains the core. The protein mix, the purified complex, or the lysate is already accessible. Buffer, dose, and time can be written. That control is a tube advantage. It is not a method for simulating various physiological environments. Changing pH or ionic strength changes who can react. It does not recreate a cell.

Lysate crosslinking is still in vitro. Two reconstituted proteins are still in vitro. Neither is a screen of an organism. For what a two-protein tube must contain, What Reagents Are Required for In Vitro Cross-Linking of Two Purified Proteins provides a complementary in-vitro reagent page.

An artificial environment can produce pairs that never existed in the cell, and it can miss pairs that required a missing partner or a membrane. Those are sample-state errors. They are not a generic false-positive and false-negative tax on every in-vitro tube. Reagent choice and a written quench still decide whether leftover chemistry continues after the intended pulse.

Coupling the tube to liquid chromatography–tandem mass spectrometry (LC-MS/MS) can report sites if the digest is searched as linked peptides. The spacer remains a reach estimate. The file does not measure a distance.

Figure 1. Left: protein or lysate, often BS3 or a DMSO spike of DSS. Right: intact cells, a permeable reagent, quench then lyse. Tissue work is a third claim.

Name whether the amines are already accessible before naming the experiment in vivo. A living-cell slogan does not attach to a lysate pulse.

In-Cell Work, Often Called In Vivo

The original living-cell-or-tissue sentence is two claims. Intact cultured cells are the common in-cell experiment. Tissue or animal crosslinking is a separate, rarer protocol. Both use a reagent that can reach the intended compartment. DSS and formaldehyde are the usual permeable amine reagents. BS3 stays outside membranes and is the wrong first solid for an intracellular in-cell pulse. For that site-first choice, How to Select a Crosslinker for XL-MS Structural Studies provides a complementary selection page.

The pulse can write links before lysis. That is the useful contrast with an already-open tube. It does not leave cellular architecture undisrupted. An NHS ester or an aldehyde is a chemical perturbation. Dose, time, and handling still have to be written to limit over-linking and cell death. Cytotoxicity is a pulse failure, not proof that a more complete interactome was captured.

In-cell data are not automatically more reliable than tube data. The digest is more complex. Background amines, permeability, and residual reagent after a poor quench all rise. Advanced separation is a practical need. It is not a guarantee of a physiological interaction.

A no-crosslinker arm is processed through the same quench, lysis, and assay. Changing only the treated flask mixes a handling effect with a reagent effect.

What Each State Can Support

These uses hold only with the condition in the same sentence.

An already-open tube can test whether two purified proteins or a defined complex can form a reagent-dependent pair or a gel shift. It cannot validate a cellular interaction by being cleaner.

An in-cell pulse can support proximity that existed before the pellet was opened, if the pair returns and falls in the no-reagent arm. It cannot grant a real biological environment or a preferred method for physiological context.

Running the tube first and the cell later is one experimental history. It is not a high-throughput screening pipeline followed by in vivo validation. In-vitro crosslinking is a poor first screen of unknown cellular partners. That job is closer to a capture table. For the three readouts that use the pulse, What Are the Specific Experimental Methods for Cross-Linking Protein Interaction Analysis provides a complementary methods page.

Figure 2. Tube: written dose on an open sample. In-cell: links before lysis, higher complexity. MS names pairs. It does not name distances.

What the Original Comparison Cannot Support

Pivotal, indispensable, and future-biomedical language sits outside the comparison. The choice is the compartment and the next table, not a vote for scientific rigor.

Figure 3. Keep: already-open versus intact cells, bifunctional reagent, written dose. Not granted: simulated physiology, measured distances, or in-cell as the more reliable method.

Experimental Limits

The comparison reduces a project to one compartment, one reagent class, one quench, and one named assay. Diagnostic language about physiological function sits outside ordinary research reporting unless a separately validated assay is in place.

Project Planning and Service Scope

A usable plan names the sample state, the permeability of the reagent, the quench, and the table that will be allowed, before the first pulse. MtoZ Biolabs scopes crosslinking MS with Orbitrap-class LC-MS/MS. Interpretability still follows those arms, not an in-vivo-is-more-reliable slogan.

Once the next sentence is a cellular partner list rather than a pair from either state, the project should not be forced through this comparison. Researchers who need that pellet can review the MtoZ Biolabs Protein-Protein Interaction Analysis Service for project-specific sample evaluation, feasibility assessment, and workflow planning.

Frequently Asked Questions

1. What is the difference between in vitro and in vivo crosslinking?

In vitro treats an already-open protein or lysate. In-cell work, often called in vivo here, treats intact cells with a permeable reagent.

2. Does in-cell crosslinking capture interactions without disrupting architecture?

No. The reagent is a chemical perturbation. Links can form before lysis. Architecture is not left untouched.

3. Can in vitro crosslinking simulate physiological conditions by changing pH and salt?

No. Those knobs change who reacts. They do not recreate a cell.

4. Does mass spectrometry confirm crosslinking distances?

No. It can name linked peptides. The spacer is a reach estimate.

5. Should in vitro screening be followed by in vivo validation?

Not as a default pipeline. Choose the compartment from the next table, not from a screening slogan.

Reference

1. Leitner A., Walzthoeni T., Kahraman A., et al. (2014). Probing native protein structures by chemical cross-linking, mass spectrometry, and bioinformatics. Nat. Protoc., 9, 120-135. https://doi.org/10.1038/nprot.2013.168
2. O'Reilly F.J., Rappsilber J. (2018). Cross-linking mass spectrometry: methods and applications in structural, molecular and systems biology. Nat. Struct. Mol. Biol., 25, 1000-1008. https://doi.org/10.1038/s41594-018-0147-0
3. Yu C., Huang L. (2018). Cross-linking mass spectrometry: an emerging technology for interactomics and structural biology. Anal. Chem., 90, 144-165. https://doi.org/10.1021/acs.analchem.7b04431
4. Sinz A. (2018). Cross-linking/mass spectrometry for studying protein structures and protein-protein interactions: where are we now and where should we go from here? Angew. Chem. Int. Ed., 57, 6390-6396. https://doi.org/10.1002/anie.201709559
5. Merkley E.D., Rysavy S., Kahraman A., et al. (2014). Distance restraints from crosslinking mass spectrometry: mining a molecular dynamics database to evaluate lysine-lysine distances. Protein Sci., 23, 747-759. https://doi.org/10.1002/pro.2458